NCT06904378View on ClinicalTrials.gov

Ontegimod and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

May 31, 2028

Study Completion Date

May 31, 2029

Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

Ontegimod

Per assigned dose level.

DRUG

Gemcitabine

The dose of gemcitabine is 1000 mg/m\^2.

DRUG

Nab paclitaxel

The dose of nab-paclitaxel is 125 mg/m\^2.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Washington University School of Medicine

OTHER

NCT06904378 - Ontegimod and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma | Biotech Hunter | Biotech Hunter